Across all five tested pancreatic cell lines paclitaxel and docetaxel were the most synergistic with ADI-TRAIL suggesting that ADI-TRAIL combination with tubulin inhibitors could be effective in pancreatic cancer treatment. The gene discussed is TNFSF10; the disease is familial pancreatic carcinoma.